Autore/Fonte: Institute of Cancer Research
Percorsi personalizzati contro il cancro legati al gene BRCA
Leggi →
3 Ottobre 2024
Questo è quello che abbiamo trovato per te
Autore/Fonte: Institute of Cancer Research
Accuratezza pari o maggiore dei calcolatori in uso
L’Iniziativa promossa da Lilt (Lega italiana per la lotta contro i tumori) mette a disposizione un numero verde per effettuare le visite negli ambulatori aderenti
A 14-day monitor detected more atrial fibrillation but did not affect hospitalization rates for stroke or hemorrhage.
Fino a oggi era fissata a 50 anni. Si parte nel 2025
Annals of Internal Medicine, Ahead of Print.
Annals of Internal Medicine, Ahead of Print.
In 2009, the first state dense breast legislation was passed in Connecticut, requiring that women who undergo mammography receive written notification of breast density. This advocacy-driven policy was intended to raise women’s awareness that dense breasts are a risk factor for breast cancer and can also obscure breast cancer on mammography. Since then, 37 states and the District of Colombia have followed with their own reporting laws, and beginning in September 2024, the US Food and Drug Administration will require breast density notification to be included in mammography reports for all patients and their referring clinicians.
This model-based comparative effectiveness analysis examines the long-term benefits and harms of digital breast tomosynthesis and supplemental breast magnetic resonance imaging screening by breast density using data on screening performance from the Breast Cancer Surveillance Consortium.
Use of MRI led to fewer biopsies and fewer diagnoses of clinically insignificant cancer.
In a large observational study, women with false-positive results were less likely to return for future screening.
Visita all’Istituto di oncologia molecolare di Fondazione Airc
New England Journal of Medicine, Volume 391, Issue 12, Page 1083-1095, September 26, 2024.
Background
With the potential to identify a vast number of rare diseases soon after birth, genomic newborn screening (gNBS) could facilitate earlier interventions and improve health outcomes. Designing a gNBS programme will involve balancing stakeholders’ opinions and addressing concerns. The views of medical students—future clinicians who would deliver gNBS—have not yet been explored.
Methods
We conducted a nationwide online survey of UK medical students via the REDCap platform. Perceptions of gNBS, including scope of testing and potential benefits and drawbacks, were explored using a mix of multiple-choice questions, Likert scales, visual analogue scales and free-text questions.
Results
In total, 116 medical students across 16 universities participated. Overall, 45% supported gNBS, with a positively skewed mean support score of 3.24 (SD 1.26, range: 1.0–5.0), and 55% felt it relevant to their future practice. Almost all agreed that infant-onset and childhood-onset diseases and conditions with effective treatments should be included. Most felt that earlier interventions and personalised care would be the most important benefit of gNBS. Other perceived benefits included earlier diagnoses, diagnosing more patients and enabling research for new treatments. However, several perceived challenges were highlighted: risk of genomic discrimination, incidental or uncertain findings, data security and breaching children’s future autonomy. Students expressed conflicting opinions on the psychological impact on families, but most were concerned about a lack of support due to current resource limitations in health services. Students frequently reported having insufficient knowledge to form an opinion, which may reflect gaps in genomics education at medical school and the current lack of evidence base for gNBS.
Conclusion
Although some support for gNBS was demonstrated, ethicolegal and social challenges were raised, emphasising a need for ongoing discussions about the implications of gNBS.
Adding radiation to NACT increased the R0 resection rate, prolonged the PFS, and potentially improved OS in selected patients with initially unresectable LACC. The trial findings indicate that this approach is safe, feasible, and may confer a survival benefit.
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Despite evidence that screening effectively reduces incidence and mortality, screening is suboptimal, especially in safety net healthcare systems and federally qualified health centers (FQHCs). Safety net healthcare systems represent 25% of U.S. hospitals and are defined as hospitals that organize and deliver a significant level of healthcare and other related services to individuals without insurance, receiving Medicaid, and other vulnerable patients.